Bhubaneswar: India may possibly get it’s COVID-19 vaccine, Covishield, by December 2020 and in the market by March next year. The happy news was revealed by the Serum Institute of India (SII) revealed amid the ongoing trial of AstraZeneca-Oxford vaccine.
“India may get COVID-19 vaccine by March 2021 provided the regulators signal with the processes fast as multiple manufacturers are working on it,” Dr Jadhav said yesterday at the India Vaccine Accessibility E-Summit organized by HEAL Foundation in association with ICCIDD. He added that by March 2021, India will get 60-70 million doses of Covishield vaccine, if everything is streamlined.
Once it is available for sale, the SII will continue manufacturing more Covishield vaccines.
“India is heading fast towards vaccine development as two manufacturers are already in phase-3 trial and one in the phase-2 trial, while more players are joining the race,” the Indian Express quoted Jadhav as saying. The report also said that the vaccine maker wants to be more inclusive as far as the variety of participants is concerned. The pharma company wants to cover older individual and people with health conditions.
Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said. The collaboration takes forward an initial agreement signed in August by Serum, GAVI and the Gates Foundation for 100 million doses to be priced at a maximum of $3 each.
The total funding provided is now $300 million, and the expanded collaboration also has an option for the provision of additional doses as needed.